Loading clinical trials...
Loading clinical trials...
A Phase 1 Clinical Study of DSP-2033 (Alvocidib) in Combination With Cytarabine/Mitoxantrone or Cytarabine/Daunorubicin (7+3) in Patients With Acute Myeloid Leukemia
Conditions
Interventions
Alvocidib
Cytarabine
+3 more
Locations
11
Japan
Fukui University Hospital
Yoshida-gun, Fukui, Japan
Chugoku Central Hospital
Fukuyama, Hiroshima, Japan
Hokkaido University Hospital
Sapporo, Hokkaido, Japan
University of Tsukuba Hospital
Tsukuba, Ibaraki, Japan
Tokai University Hospital
Isehara, Kanagawa, Japan
Osaka City Hospital Organization
Miyakojima-ku, Osaka, Japan
Start Date
May 15, 2018
Primary Completion Date
March 31, 2020
Completion Date
March 31, 2020
Last Updated
April 12, 2022
NCT06285890
NCT06220162
NCT04065399
NCT04628026
NCT06484062
NCT06994676
Lead Sponsor
Sumitomo Pharma Co., Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions